Cargando…

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder

OBJECTIVE: This multicenter, multinational, cross‐sectional study aimed to investigate clinical characteristics and treatment outcomes associated with augmentation/combination treatment strategies in major depressive disorder (MDD). METHOD: Sociodemographic, clinical, and treatment features of 1410...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dold, M., Bartova, L., Mendlewicz, J., Souery, D., Serretti, A., Porcelli, S., Zohar, J., Montgomery, S., Kasper, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947736/ https://www.ncbi.nlm.nih.gov/pubmed/29492960 http://dx.doi.org/10.1111/acps.12870

Ejemplares similares

PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers
por: Bartova, Lucie, et al.
Publicado: (2016)

Psychotherapy employed additionally to Psychopharmacotherapy is not related to Better Treatment Outcome in Major Depressive Disorder
por: Bartova, L., et al.
Publicado: (2022)

Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression
por: Fugger, Gernot, et al.
Publicado: (2020)

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
por: Bartova, Lucie, et al.
Publicado: (2021)

Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)
por: Dold, Markus, et al.
Publicado: (2018)

The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
por: Fugger, Gernot, et al.
Publicado: (2022)

Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression
por: Bartova, Lucie, et al.
Publicado: (2021)

Age as a moderating factor of treatment resistance in depression
por: Kautzky, Alexander, et al.
Publicado: (2023)

Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample
por: Zaninotto, Leonardo, et al.
Publicado: (2015)

Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study
por: Kautzky, A., et al.
Publicado: (2018)

The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study
por: Schosser, Alexandra, et al.
Publicado: (2017)

Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database
por: Kraus, Christoph, et al.
Publicado: (2023)

The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives
por: Fabbri, Chiara, et al.
Publicado: (2018)

PS87. An update on prediction of treatment outcome in treatment resistant depression
por: Kautzky, Alexander, et al.
Publicado: (2016)

A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping
por: Fabbri, Chiara, et al.
Publicado: (2020)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation
por: Fanelli, Giuseppe, et al.
Publicado: (2022)

Clinical correlates and prognostic implications of severe suicidal ideation in major depressive disorder
por: Olgiati, Paolo, et al.
Publicado: (2023)

Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment
por: Fabbri, Chiara, et al.
Publicado: (2020)

Antidepressant emergent mood switch in major depressive disorder: onset, clinical correlates and impact on suicidality
por: Olgiati, Paolo, et al.
Publicado: (2023)

Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder
por: Olgiati, Paolo, et al.
Publicado: (2022)

Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited
por: Bartova, Lucie, et al.
Publicado: (2022)

Silexan for treatment of anxiety and depression in the context of COVID-19
por: Bartova, Lucie, et al.
Publicado: (2023)

A New Characterization of Mental Health Disorders Using Digital Behavioral Data: Evidence from Major Depressive Disorder
por: Taliaz, Dekel, et al.
Publicado: (2021)

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
por: Fabbri, Chiara, et al.
Publicado: (2020)

Possible Modulatory Role of ARC Gene Variants in Mood Disorders
por: Crisafulli, Concetta, et al.
Publicado: (2021)

Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder
por: Porcelli, Stefano, et al.
Publicado: (2014)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: Nelson, J Craig, et al.
Publicado: (2008)

How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach
por: Fabbri, Chiara, et al.
Publicado: (2020)

Familiality and SNP heritability of age at onset and episodicity in major depressive disorder
por: Ferentinos, P., et al.
Publicado: (2015)

Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs
por: Kato, M, et al.
Publicado: (2015)

Post-traumatic stress disorder and childhood emotional abuse are markers of subthreshold bipolarity and worse treatment outcome in major depressive disorder
por: Olgiati, Paolo, et al.
Publicado: (2021)

Clinical Utility of Fluid Biomarker in Depressive Disorder
por: Serretti, Alessandro
Publicado: (2022)

A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
por: Lee, Kyung Ho, et al.
Publicado: (2021)

Anhedonia and Depressive Disorders
por: Serretti, Alessandro
Publicado: (2023)

Combination/augmentation strategies for improving the treatment of depression
por: Moret, Chantal
Publicado: (2005)

Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials
por: Dold, Markus, et al.
Publicado: (2023)

Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
por: Dold, Markus, et al.
Publicado: (2015)

Combining machine learning algorithms for prediction of antidepressant treatment response
por: Kautzky, Alexander, et al.
Publicado: (2020)

Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review
por: Caldiroli, Alice, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tc9tv90r2h1eilu8bmeae8mmnn